MannKind Breathes Easier After FDA Diabetes Safety Guidance
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MannKind is reassuring investors that its fast-acting inhaled insulin product Afresa, due for a U.S. filing soon, is likely to satisfy new FDA guidelines for cardiovascular safety of diabetes drugs
You may also be interested in...
Guidance To Cut Diabetes Drug CV Risk Gets First Test With Pending NDAs
FDA’s flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late-stage development.
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs
FDA's flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late stages of development
MannKind Says Inhaled Insulin NDA On Track, Resumes Search For Partner
Afresa Phase III studies are complete, though FDA wants bioequivalence trial to support new inhaler device.